


JP 1614
#6
YC
61202

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE WAS DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON: May 30, 2002

Edward R. Gimmi
Attorney for Applicants


Signature

Attorney Docket No.: P51160

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Erskine, *et al.* May 30, 2002
Serial No.: 09/912,483 Group Art Unit: 1614
Filed: July 25, 2001 Examiner: James H. Reamer
For: Compounds and Methods for the Treatment of Neoplastic Disease

RECEIVED

RESPONSE TO RESTRICTION REQUIREMENT

JUN 12 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This paper is in response to the Restriction Requirement dated May 7, 2002 (Paper No. 5) (herein referred to as "the Restriction Requirement"), setting forth a thirty (30) day shortened statutory period for reply. As this response is timely filed within the shortened statutory period for response of thirty (30) days, no fee is required. Please charge any additional requisite fees relating to this amendment and response to Deposit Account No. 19-2570.

Restriction Requirement Under 35 U.S.C. §§ 121 and 372

In response to the Restriction Requirement, the Applicants elect Group I consisting of Claims 1 to 26, 37, and 38 with traverse. The Applicants reserve the right to prosecute, in one or more patent applications, the canceled claims, the claims to non-elected inventions, the


Serial No.: 09/912,483

-2-

Group Art No.: 1614

claims as originally filed, and any other claims supported by the specification.

Respectfully submitted,


Edward R. Gimmi
Attorney for Applicants
Registration No. 38,891

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-4478
Facsimile (610) 270-5090

BEST AVAILABLE COPY